YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Solid Biosciences Inc. CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac di…
(RTTNews) - Although the idea of gene therapy was first proposed in the 1960s, it took many years of research before it became a reality. In 2017, the first gene therapy - Novartis' Kymriah - was approved for the treatment of children and…
Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative ther…
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of…
Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged more than 190% over the past 12 months. An…
* Solid Biosciences press release [https://seekingalpha.com/pr/20445553-solid-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (SLDB [https://seekingalpha.com/symbol/SLDB]): Q4 GAAP EPS of -$0.53 misses…
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003 has been generally well tolerated in the…
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in…
Solid Biosciences Inc. CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced tha…
March S&P 500 E-Mini futures (ESH26) are trending down -0.53% this morning as Treasury yields continued to rise after another surge in oil prices stoked concerns that the Middle East conflict would drive inflation higher. The 10-year T-not…
The S&P 500 Index ($SPX) (SPY) on Thursday closed down -0.56%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -1.61%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.29%. March E-mini S&P futures (ESH26) fell -0.60%, and…
(RTTNews) - Solid Biosciences Inc. (SLDB) announced that it has received positive regulatory feedback from a recent Type C meeting with the U.S FDA, marking a key step forward for its gene therapy candidate SGT-003 in Duchenne muscular dys…
Sarepta Therapeutics stock jumped after the company unveiled positive top-line results for a study measuring the efficacy of Elevidys, its controversial blockbuster treatment for Duchenne muscular dystrophy. Patients in the study showed “s…
Clinical-stage biopharmaceutical company Keros Therapeutics KROS is developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth fa…
[Duchenne muscular dystrophy genetic test] Hailshadow/iStock via Getty Images Solid Biosciences (SLDB [https://seekingalpha.com/symbol/SLDB]) traded higher on Wednesday after the gene therapy developer announced full enrollment in a Phase…
(RTTNews) - Solid Biosciences Inc. (SLDB), a neuromuscular and cardiac disease medicine developer, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SGT-212 for the treatment of Friedreich's…
CHARLESTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 7…
[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] French biotech (ABVX [https://seekingalpha.com/symbol/ABVX]) has emerged as the most likely acquisition target among biotechs in 2026, significantly ou…
(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by investor sentiment and sector momentum…
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target. Blum noted that the recent deaths o…
CHARLESTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 2…
– SGT-212 has been granted FDA Rare Pediatric Disease and Fast Track designations – – SGT-212 is the only dual route gene therapy in development to treat Friedreich’s ataxia – – FALCON Phase 1b clinical trial participant screening underway…
- Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organization (CDMO) - - AAV-SLB101 has been gene…
Solid Biosciences Inc. - Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique,…
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, end-to-end regulatory…
Solid Biosciences Inc. CHARLESTOWN, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac dis…
Company Logo The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized stra…
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 1…
CHARLESTOWN, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPI…
- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is…
CHARLESTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced…
Solid Biosciences Inc. (NASDAQ:SLDB) is entering a critical phase in its development of gene therapies for rare neuromuscular and cardiac diseases. The biotechnology company’s lead candidate, SGT-003 for Duchenne muscular dystrophy (DMD),…
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company specializing in RNA-targeted therapeutics for rare neuromuscular diseases, finds itself at a critical juncture. With a market capitalization of approximately $2 billion and…
- Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to discuss regulatory pathways with U.S. FDA in Q4 2025 - - FA (SGT-212): Phase 1b trial initiation expected in Q4 202…
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 5…